Girona

• A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with sea … Ended
  2023-506189-29-00 4 2023-09-04 SARS-CoV-2 and Influenza
• Phase 3 Study Comparing Zimberelimab with Domvanalimab to Pembrolizumab in Advanced Non-Small Cell Lung Cancer Ended
  2022-503071-28-00 5 2023-08-31 Squamous Non-small cell Lung Cancer
• A pivotal, multicentre, randomised, open-label, parallel-group trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgest … Ended
  2022-502024-51-00 5 2023-07-12 Prevention of pregnancy
• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended
  2022-500536-11-01 5 2023-06-08 Moderately to severely active ulcerative colitis
• Open-label, Multi-centre, Non-Inferiority study of safety and immunogenicity of BIMERVAX as heterologous booster for the prevention of coron … Ended
  2023-504639-42-00 4 2023-05-26 SARS-CoV-2 infection
• A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Ended
  2023-504111-33-00 4 2023-02-14 Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or F
• A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patient … Ended
  2023-506837-31-00 4 2023-01-27 New onset type I diabetes
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Ep … Ended
  2024-513230-38-00 5 2022-12-15 Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peri
• Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat … Ended
  2024-514714-12-00 10 2022-11-11 Metastatic Pancreatic Ductal Adenocarcinoma
• A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TI … Ended
  2023-504270-38-00 4 2022-10-18 In participants with PD-L1–positive and systemic therapy–naive R/M SCC
• To Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myelo … Ended
  2024-510644-31-00 3 2022-06-10 Relapsed/Refractory Multiple Myeloma
• A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Tr … Ended
  2024-511561-10-00 4 2022-05-31 Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
• A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose comb … Ended
  2024-518527-29-00 4 2022-05-24 Polycystic ovary syndrome (PCOS)
• ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion Ended
  2023-508454-26-00 6 2022-05-01 Acute Ischemic Stroke
• Phase 2 Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ended
  2023-504825-38-00 4 2022-04-15 Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
• A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) Ended
  2024-514372-40-00 5 2022-04-12 Anterior ST-Elevation Myocardial Infarction
• Predicting olaparib sensitivity in metastatic HER2-negative breast cancer with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutation or RAD51-negat … Ended
  2024-511875-14-00 4 2022-03-24 Pre and post-menopausal women and men with unresectable locally advanc
• A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents … Ended
  2024-513304-33-00 5 2022-03-17 Type 1 diabetes mellitus
• Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants with Relapsed or Refractory Multiple Myeloma (DREAM … Ended
  2023-508213-16-00 4 2022-03-15 Multiple Myeloma
• A study to evaluate ExPEC9V vaccine for the prevention of Invasive E. coli Disease in adults aged 60 years and older with a history of urina … Ended
  2023-506589-30-00 5 2022-02-09 Invasive Extraintestinal Pathogenic Escherichia coli Disease
• Phase II Study of efti plus pembrolizumab combination therapy for head and neck cancer (HNSCC). Ended
  2024-510762-16-00 4 2021-11-30 Metastatic head and neck squamous cell carcinoma (HNSCC)
• A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Plac … Ended
  2024-511066-36-00 5 2021-10-13 Light Chain (AL) Amyloidosis
• A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended
  2023-505203-23-01 5 2021-07-26 Severe asthma with an eosinophilic phenotype

Showing 241–264 of 287 trials